HUE059838T2 - Seladelpar primer epe cholangitis kezelésére - Google Patents

Seladelpar primer epe cholangitis kezelésére

Info

Publication number
HUE059838T2
HUE059838T2 HUE17722943A HUE17722943A HUE059838T2 HU E059838 T2 HUE059838 T2 HU E059838T2 HU E17722943 A HUE17722943 A HU E17722943A HU E17722943 A HUE17722943 A HU E17722943A HU E059838 T2 HUE059838 T2 HU E059838T2
Authority
HU
Hungary
Prior art keywords
seladelpar
treatment
primary biliary
biliary cholangitis
cholangitis
Prior art date
Application number
HUE17722943A
Other languages
English (en)
Inventor
Pol Boudes
Charles Mcwherter
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of HUE059838T2 publication Critical patent/HUE059838T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE17722943A 2016-05-31 2017-04-26 Seladelpar primer epe cholangitis kezelésére HUE059838T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662343688P 2016-05-31 2016-05-31

Publications (1)

Publication Number Publication Date
HUE059838T2 true HUE059838T2 (hu) 2023-01-28

Family

ID=58699276

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17722943A HUE059838T2 (hu) 2016-05-31 2017-04-26 Seladelpar primer epe cholangitis kezelésére

Country Status (25)

Country Link
US (5) US10272058B2 (hu)
EP (1) EP3463328B1 (hu)
JP (1) JP7079735B2 (hu)
KR (1) KR102408288B1 (hu)
CN (1) CN109195594A (hu)
AU (1) AU2017274293B2 (hu)
BR (1) BR112018074147A2 (hu)
CA (1) CA3024155C (hu)
DK (1) DK3463328T3 (hu)
ES (1) ES2921230T3 (hu)
HR (1) HRP20220903T1 (hu)
HU (1) HUE059838T2 (hu)
IL (1) IL263372B2 (hu)
LT (1) LT3463328T (hu)
MX (1) MX2018014915A (hu)
NZ (1) NZ748721A (hu)
PL (1) PL3463328T3 (hu)
PT (1) PT3463328T (hu)
RS (1) RS63345B1 (hu)
RU (1) RU2765460C2 (hu)
SG (1) SG11201810123SA (hu)
SI (1) SI3463328T1 (hu)
UA (1) UA122719C2 (hu)
WO (1) WO2017209865A1 (hu)
ZA (1) ZA201808360B (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CN106102734B (zh) 2014-03-20 2019-05-14 西玛贝医药公司 肝内胆汁淤积性疾病的治疗
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
AU2019378845A1 (en) * 2018-11-16 2021-06-03 Cymabay Therapeutics, Inc. Combination treatment of NAFLD and NASH
US20220241228A1 (en) * 2021-02-01 2022-08-04 Cymabay Therapeutics, Inc. Treatment of cholangiopathies

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
JPH10512894A (ja) 1995-03-06 1998-12-08 アイシス・ファーマシューティカルス・インコーポレーテッド 2’−o−置換ピリミジンおよびそのオリゴマー化合物の合成の改良法
EP0882061B1 (en) 1996-02-14 2004-05-19 Isis Pharmaceuticals, Inc. Sugar-modified gapped oligonucleotides
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7981915B2 (en) 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
ES2378435T3 (es) 2003-09-19 2012-04-12 Janssen Pharmaceutica N.V. �?cidos 4-((fenoxialquil)tio)-fenoxiacéticos y análogos
JP5697296B2 (ja) 2004-03-05 2015-04-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 高脂血症および高コレステロール血症に関連する障害または疾患を、副作用を最小限にしつつ処置するための方法
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
EP2346498B1 (en) 2008-10-17 2018-12-26 Cymabay Therapeutics, Inc. Methods of reducing small, dense ldl particles
EP2424521A4 (en) * 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE
MA34097B1 (fr) 2010-03-30 2013-03-05 Novartis Ag Utilisations d'inhibiteurs de dgat1
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
JP2017505285A (ja) 2013-11-20 2017-02-16 サイマベイ・セラピューティクス・インコーポレイテッドCymaBay Therapeutics,Inc. ホモ接合性家族性高コレステロール血症の治療
US20160279085A1 (en) 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
CN106102734B (zh) 2014-03-20 2019-05-14 西玛贝医药公司 肝内胆汁淤积性疾病的治疗
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
RS59637B1 (sr) 2014-04-11 2020-01-31 Cymabay Therapeutics Inc Tretiranje nafld i nash
KR20170020514A (ko) 2014-06-26 2017-02-22 사이머베이 쎄라퓨틱스, 인코퍼레이티드 중증 고중성지방혈증의 치료
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
PL3687523T3 (pl) 2017-09-26 2022-02-21 Cymabay Therapeutics, Inc. Leczenie świądu cholestatycznego za pomocą seladelparu
AU2019378845A1 (en) 2018-11-16 2021-06-03 Cymabay Therapeutics, Inc. Combination treatment of NAFLD and NASH
WO2020102351A1 (en) 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications

Also Published As

Publication number Publication date
SI3463328T1 (sl) 2022-08-31
UA122719C2 (uk) 2020-12-28
KR102408288B1 (ko) 2022-06-10
BR112018074147A2 (pt) 2019-03-06
EP3463328A1 (en) 2019-04-10
AU2017274293B2 (en) 2022-03-31
KR20190015363A (ko) 2019-02-13
ZA201808360B (en) 2020-02-26
US20170340589A1 (en) 2017-11-30
RU2018146504A (ru) 2020-07-09
US20210000774A1 (en) 2021-01-07
US11596614B2 (en) 2023-03-07
RS63345B1 (sr) 2022-07-29
IL263372B2 (en) 2023-06-01
IL263372A (en) 2018-12-31
EP3463328B1 (en) 2022-06-15
LT3463328T (lt) 2022-08-10
PT3463328T (pt) 2022-07-07
DK3463328T3 (da) 2022-07-04
HRP20220903T1 (hr) 2022-10-14
US20190255004A1 (en) 2019-08-22
CA3024155C (en) 2023-10-10
WO2017209865A1 (en) 2017-12-07
JP2019518022A (ja) 2019-06-27
US10813895B2 (en) 2020-10-27
CA3024155A1 (en) 2017-12-07
US10272058B2 (en) 2019-04-30
SG11201810123SA (en) 2018-12-28
RU2765460C2 (ru) 2022-01-31
NZ748721A (en) 2022-04-29
US20200061006A1 (en) 2020-02-27
US20210220305A1 (en) 2021-07-22
RU2018146504A3 (hu) 2020-07-27
US11000494B2 (en) 2021-05-11
CN109195594A (zh) 2019-01-11
JP7079735B2 (ja) 2022-06-02
ES2921230T3 (es) 2022-08-22
US10478411B2 (en) 2019-11-19
PL3463328T3 (pl) 2022-10-03
MX2018014915A (es) 2019-04-24
AU2017274293A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
HK1247202A1 (zh) 用於治療癌症的化合物
ZA201903649B (en) Treatment for primary biliary cholangitis
IL279627A (en) A method for treating depression
IL275482A (en) Asketamine for the treatment of depression
DK3143025T3 (da) Forbindelser til behandling af spinal muskelatrofi
IL266012A (en) Combination therapy for c3 inhibition
PL3524255T3 (pl) Kompozycja do leczenia trądziku
HK1244485A1 (zh) 用於治療神經母細胞瘤的組合物
PT3506904T (pt) Tratamento de demência
SI3463328T1 (sl) Seladelpar za zdravljenje primarnega biliarnega holangitisa
ZA201800869B (en) Continuous process for the treatment of wastewater
AP2016009497A0 (en) Process for the treatment of high sulphate waters
HK1247558A1 (zh) 塞內可瑞偉洛克(cenicriviroc)用於治療纖維化
PL3484475T3 (pl) 1-Metylonikotynamid do leczenia choroby układu krążenia
ZA202001536B (en) Method for the treatment of wastewaters
GB201603546D0 (en) Treatment of urine
PL3292226T3 (pl) Sposób obróbki szlamu zawierającego żelazo
HK1210590A1 (en) Method for the treatment of hypercholesterolemia
PL3431656T3 (pl) Sposób obróbki kamieni tłuczniowych
PL3630754T3 (pl) Związki izoindolinoacetylenowe do leczenia nowotworu
ZA201906542B (en) Process for the treatment of wastewater
ZA201704589B (en) Compounds for the treatment of cancer
GB201701928D0 (en) Compounds for the treatment of hyperglycaemia
GB201701936D0 (en) New methods for the treatment of hyperglycaemia
GB201701933D0 (en) New methods for the treatment of hyperglycaemia